Sharma Anand, Patnaik Itish, Kumar Ashok, Gupta Rohit
Department of Gastroenterology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India.
J Clin Exp Hepatol. 2021 Nov-Dec;11(6):720-726. doi: 10.1016/j.jceh.2021.06.013. Epub 2021 Jun 19.
The COVID-19 pandemic has caused mayhem globally since the beginning of 2020. Owing to the immune dysfunction inherent to cirrhosis and the poor general condition, patients with chronic liver disease (CLD) are at higher risk of mortality and morbidity due to COVID-19. Recently, a number of vaccines against SARS-Cov-2 have been approved for emergency use around the globe. Although the phase 2/3 trials of these vaccines show them to be safe and effective in the general population, data in patients with CLD are scarce. The number of patients with CLD enrolled on these trials is small, and no liver-related adverse effects have been reported yet. Various liver societies have come up with guidelines on vaccination in this population and recommend vaccination on a priority basis. Trials to assess the safety and efficacy of the COVID vaccines are underway and are likely to provide valuable insight into this matter.
自2020年初以来,新冠疫情在全球范围内造成了混乱。由于肝硬化固有的免疫功能障碍和总体健康状况不佳,慢性肝病(CLD)患者因新冠病毒感染而面临更高的死亡和发病风险。最近,一些针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗已在全球范围内获批紧急使用。尽管这些疫苗的2/3期试验表明它们在普通人群中是安全有效的,但CLD患者的数据却很稀少。参与这些试验的CLD患者数量较少,且尚未报告与肝脏相关的不良反应。各个肝脏学会已经针对这一人群制定了疫苗接种指南,并建议优先接种疫苗。评估新冠疫苗安全性和有效性的试验正在进行中,可能会为这一问题提供有价值的见解。